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Abstract
We recently reported the identification of recurrent
gene fusions in the majority of prostate cancers
involving the 5V untranslated region of the androgen-
regulated gene TMPRSS2 and the ETS family members
ERG, ETV1, and ETV4. Here we report the noninvasive
detection of these gene fusions in the urine of patients
with clinically localized prostate cancer. By quantitative
polymerase chain reaction, we assessed the expres-
sion of ERG and TMPRSS2:ERG transcripts in urine
samples obtained after prostatic massage from 19 pa-
tients (11 prebiopsy and 8 pre–radical prostatectomy)
with prostate cancer. We observed a strong concor-
dance between ERG overexpression and TMPRSS2:
ERG expression, with 8 of 19 (42%) patients having
detectable TMPRSS2:ERG transcripts in their urine.
Importantly, by fluorescence in situ hybridization, we
confirmed the presence or the absence of TMPRSS2:
ERG gene fusions in matched prostate cancer tissue
samples from three of three patients with fusion tran-
scripts in their urine and from two of two patients
without fusion transcripts in their urine. These results
demonstrate that TMPRSS2:ERG gene fusions can be
detected in the urine of patients with prostate cancer
and support larger studies on prospective cohorts for
noninvasive detection of prostate cancer.
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Introduction
Chromosomal rearrangements play causal roles in numer-
ous human malignancies and have been exploited diagnos-
tically and therapeutically [1,2]. Using a novel bioinformatics
strategy to nominate candidate oncogenes, we identified
recurrent gene fusions involving the 5V untranslated region of
the androgen-regulated gene TMPRSS2 to members of the
ETS gene family (ERG, ETV1, or ETV4) in the majority of
prostate cancers [3,4]. Subsequently, multiple studies have
confirmed the presence of TMPRSS2:ETS gene fusions, par-
ticularly TMRPSS2:ERG, in 40% to 80% of prostate cancers
[5–8]. In addition to likely playing a central role in the patho-
genesis of prostate cancers, these studies highlight the po-
tential of TMPRSS2:ETS gene fusions to serve as a specific
biomarker of prostate cancer.
In an effort to develop a noninvasive method to detect
TMPRSS2:ERG gene rearrangements, we explored the possi-
bility of identifying this fusion in urine samples obtained from
patients with prostate cancer using quantitative polymerase
chain reaction (qPCR). Here we show that RNA isolated from
sedimented urine and subjected to qPCR revealed the pres-
ence of TMPRSS2:ERG fusions in 8 of 19 (42%) patients with
prostate cancer. We validated the specificity of this assay
by confirming the presence or the absence of TMPRSS2:ERG
gene rearrangements in matched tissue samples from a sub-
set of our cohort. The results demonstrate the feasibility of the
noninvasive detection of TMRPSS2:ETS gene fusions from
the urine of patients with prostate cancer.
Materials and Methods
Urine Collection, RNA Isolation, and Amplification
This study was approved by the Institutional Review Board
(IRB) of the University of Michigan Medical School (Ann Arbor,
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MI). With informed consent of the patients, urine samples
were obtained following a digital rectal exam before either
needle biopsy or radical prostatectomy. Urine was voided into
urine collection cups containing DNA/RNA preservative
(Sierra Diagnostics LLC, Sonora, CA). For RNA isolation, a
minimum of 30 ml of urine was centrifuged at 4000 rpm for
15 minutes at 4jC. RNAlater (Ambion, Inc., Austin, TX) was
added to urine sediments and stored at 20jC until RNA
isolation. Total RNA was isolated using an RNeasy Micro kit
(Qiagen, Inc., Valencia, CA) according to the manufacturer’s
instructions. RNA integrity was verified using an Agilent
2100 Bioanalyzer. Total RNA was amplified using an Omni-
Plex Whole Transcriptome Amplification (WTA) kit (Rubicon
Genomics, Ann Arbor, MI) according to the manufacturer’s
instructions, essentially as previously described [9]. Twenty-
five nanograms of total RNA was used for WTA library syn-
thesis, and cDNA library was subjected to one round of WTA
PCR amplification. Amplified cDNA was purified using a
QIAquick PCR Purification kit (Qiagen, Inc.). For cell line
proof-of-concept experiments, the indicated number of VCaP
or LNCaP cells was spiked into 1 ml of urine, and samples
were processed like voided urine.
qPCR
qPCR was used to detect ERG, ETV1, and TMPRSS2:
ERG transcripts from WTA-amplified cDNA, essentially as
described [4]. For each qPCR, 10 ng of WTA-amplified cDNA
was used as template. 2 Power SYBR Green Master Mix
(Applied Biosystems, Foster City, CA) and 25 ng of both
forward and reverse primers were used for ERG, ETV1,
prostate-specific antigen (PSA), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) qPCR. 2 Taqman
Universal PCR Master Mix, a final concentration of 900 nM
forward and reverse primers, and 250 nM probe were used
for Taqman TMPRSS2:ERGa. For the Taqman assay, sam-
ples with Ct (threshold cycle) values greater than 38 cycles
were considered to show no amplification. Threshold levels
were set at the exponential phase of qPCR using Sequence
Detection Software version 1.2.2 (Applied Biosystems). The
amount of each target gene relative to the housekeeping
gene GAPDH for each sample was determined using the
comparative threshold cycle (Ct) method (Applied Bio-
systems user bulletin 2; http://docs.appliedbiosystems.com/
pebiodocs/04303859.pdf). Samples with inadequate am-
plification of PSA (Ct > 22), indicating poor recovery of
prostate cells in the urine, were excluded from further anal-
ysis. ERG (exons 5 and 6) and ETV1 (exons 6 and 7) [4],
GAPDH [10], and PSA [11] primers were as described. All
primers were synthesized by Integrated DNA Technologies
(Coralville, IA). Taqman primers and probe (MGB-labeled,
synthesized by Applied Biosystems) specific for TMPRSS2:





Fluorescence In Situ Hybridization (FISH)
We acquired matched biopsy tissues from the University
of Michigan Prostate Cancer Specialized Program of Re-
search Excellence (SPORE) Tissue Core and prostatectomy
tissue sections from the radical prostatectomy series at the
University of Michigan, which is part of the SPORE. All
samples were collected with informed consent of the patients
and prior IRB approval. Formalin-fixed paraffin-embedded
tissue sections were used for interphase FISH, as de-
scribed [3,4]. For metaphase FISH on VCaP and LNCaP
cells, metaphase spreads were prepared using standard
methods. For analysis of ERG gene rearrangement, we
used a split-signal probe strategy, with two probes spanning
the ERG locus (5V, digoxin dUTP–labeled BAC clone RP11-
95I21; 3V, biotin 14-dCTP– labeled BAC clone RP11-
476D17). All BAC clones were obtained from the Children’s
Hospital of Oakland Research Institute.
Results and Discussion
We sought to develop a method to detect the presence of
TMPRSS2:ETS fusion transcripts in prostate cancer cells
shed into the urine after a digital rectal exam. As proof of
concept, we employed urine spiked with prostate cancer
cell lines expressing high levels of ERG and TMPRSS2:
ERG (VCaP) or high levels of ETV1 (LNCaP). As shown in
Figure 1, we were able to detect ERG overexpression ex-
clusively in VCaP at 1600 cells and ETV1 overexpression
exclusively in LNCaP at 16000 cells by qPCR. By correlating
the number of spiked VCaP and LNCaP cells toGAPDH and
PSA Ct values, we observed that urine obtained from pa-
tients after a digital rectal exam contained cell numbers
insufficient to reliably detect ERG or ETV1 overexpression
(data not shown). Thus, we amplified total RNA collected
from the urine of patients with prostate cancer using Omni-
Plex WTA before qPCR analysis. We have previously vali-
dated WTA for RNA amplification before qPCR and/or DNA
Figure 1. Detection of ERG and ETV1 transcripts in urine spiked with prostate
cancer cell lines. The indicated number of LNCaP (red bar: high ETV1
expression) or VCaP (blue bar: high ERG and TMPRSS2:ERG expression)
prostate cancer cells was spiked into 1 ml of urine. Approximately 1.6 million
cells of each cell line were used without being spiked (Direct). Total RNA was
isolated and reverse-transcribed to cDNA before qPCR analysis. The relative
amount of ERG and ETV1 for each sample was normalized to the amount
of GAPDH.
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microarray analysis [9]. Using this strategy, we assessed two
cohorts containing a total of 19 men with prostate cancer.
After a digital rectal exam, urine was collected from 11 men
before the performance of needle biopsy, which revealed the
presence of prostate cancer. We also assessed a cohort of
eight patients with prostate cancer from whom urine was
collected after a digital rectal exam but before radical pros-
tatectomy. Cohort characteristics are presented in Table 1.
For each patient, we determined the expression of ERG
relative toPSA, in addition to determiningwhether the sample
expressed TMPRSS2:ERG fusion transcripts. To confirm
the specificity of our TMPRSS2:ERG Taqman primer/probe
assay, we assayed urine samples spiked with 1.6 million
LNCaP or VCaP cells. We detected TMPRSS2:ERG fusion
transcripts exclusively in VCaP cells, which we have pre-
viously shown to markedly overexpress ERG and to harbor
TMPRSS2:ERG rearrangement [4]. By this same assay, 8 of
19 (42%) urine samples expressed TMPRSS2:ERG, in-
cluding the seven samples with the highest expression of
ERG (Table 1). These results are consistent with previous
studies demonstrating an overall frequency of 40% to 80% for
TMPRSS2:ERG fusions in prostate cancer tissue samples
and demonstrating that ~95% of samples with ERG over-
expression harbor TMPRSS2:ERG gene fusions [4–8]. We
did not detect ETV1 overexpression in any sample.
As a confirmation of the specificity of our qPCR assay,
we used FISH on matched tissue samples to determine the
presence or the absence of the TMPRSS2:ERG gene re-
arrangement in the patient’s prostate cancer.We used a split-
probe FISH assay, with probes located 5V and 3V to the ERG,
where a TMPRSS2:ERG gene rearrangement is indicated
by splitting of one pair of probes or by loss of the 5V ERG
probe, which is consistent with an intrachromosomal deletion
between TMPRSS2 and ERG on chromosome 21q [4,5,8].
We expected that prostate cancer tissues from patients
with high levels of ERG and TMPRSS2:ERG transcripts in
their urine should be positive by FISH, whereas prostate
cancer from patients with low levels of ERG and no detect-
able TMPRSS2:ERG transcripts in their urine should be
negative by FISH. Thus, we assessed matched prostate tis-
sue samples from three patients with detectable TMPRSS2:
ERG in their urine and from two patients without detectable
TMPRSS2:ERG in their urine. As expected, tissues from the
three patients with high levels of ERG and detectable levels
of TMRPSS2:ERG in their urine were positive for ERG
rearrangement by FISH, whereas the two samples without
TMPRSS2:ERG in their urine were negative for ERG rear-
rangement by FISH (Table 1). Hematoxylin and eosin–
stained tissue sections and corresponding negative FISH
assay from sample 5778, and a positive FISH assay from
sample 5790 with deletion of the 5V ERG probe are shown
in Figure 2, A–D.
In summary, we have described the noninvasive detection
of TMPRSS2:ERG fusion transcripts in the urine of patients
with prostate cancer. We and others have recently described
the presence of TMPRSS2:ETS gene fusions in the majority
of prostate cancers and the utility of these gene fusions as
a specific tissue biomarker of prostate cancer [3–8]. One
limitation of the TMPRSS2:ERG Taqman assay we used for
this study is that it only detects the TMPRSS2:ERGa isoform,
Table 1. Noninvasive Detection of TMPRSS2:ERG Gene Fusions in the Urine of Men with Prostate Cancer.
Sample ID Type Gleason Major Gleason Minor Gleason Score PSA (ng/ml) Age ERG Fusion (Ct) FISH
LNCaP Cell line NA NA NA NA NA 0.01 NQ 
5778 Bx 3 3 6 11.7 52 NQ NQ 
5797 RP 3 4 7 5.3 52 NQ NQ 
5892 RP 4 3 7 8.9 57 NQ NQ
5909 Bx 3 3 6 7.8 56 0.04 NQ
5918 Bx 3 3 6 3 56 0.06 NQ
5915 Bx 3 4 7 6.9 71 0.20 NQ
5798 RP 3 3 6 2.7 47 0.20 NQ
5859 RP 3 3 6 8.7 63 0.27 NQ
5893 RP 3 3 6 0.22 59 0.38 33.71
5880 RP 3 3 6 2.96 67 0.40 NQ
5796 Bx 4 5 9 19.3 82 0.98 NQ
5780 Bx 3 3 6 5.9 79 1.00 NQ
5794 Bx 3 3 6 3.8 56 1.09 38.96
5864 RP 3 4 7 5.5 49 18.06 32.65
5776 Bx 3 3 6 2.8 54 22.01 30.66 +
5775 Bx 3 3 6 5.99 62 30.91 32.87
5815 RP 3 4 7 5.4 59 206.50 31.78 +
5790 Bx 3 4 7 5.5 51 328.56 31.48 +
5912 Bx 3 4 7 15.5 67 797.86 34.13
VCaP Cell line NA NA NA NA NA 226633.25 21.66 +
Each urine specimen was obtained from a unique patient assigned an ID, and urine samples spiked with 1.6 million VCaP or LNCaP cells were also assessed. The
source of the sample, prebiopsy (Bx) or pre– radical prostatectomy (RP), is indicated. For all patients, major Gleason, minor Gleason, Gleason sum score,
prebiopsy or preprostatectomy PSA (ng/ml), and age are reported. qPCR was used to measure the amount of ERG relative to PSA for each specimen. Samples
were also assessed for the expression of TMPRSS2:ERGa using a specific Taqman assay, with positive samples indicated by the threshold cycle (Ct) of
amplification. Matched prostate cancer tissue samples for five samples were assessed by FISH for TMPRSS2:ERG fusion using a split-probe assay for ERG
rearrangement. Samples negative or positive for TMPRSS2:ERG rearrangements are indicated by () or (+), respectively. NQ, no quantifiable amplification of
ERG; ND, no detectable amplification of ERG or TMPRSS2:ERG for the respective assays.
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which is expressed in approximately 85% to 95% of fusion-
positive prostate cancers [4,7]. Thus, additional assays will
be needed to detect alternative isoforms expressed in the
remaining 10% to 20% of positive cases. Isoform-specific
assays may be particularly relevant, as particular isoforms
have been associated with aggressive disease [7]. The
presence of prostate cancer cells in the sedimented urine of
prostate cancer suggests that other approaches to detect
TMPRSS2:ETS gene rearrangements, such as urine-based
FISH similar to the UroVysion system for detecting bladder
cancer [12], may also be feasible. A FISH-based assay would
also be able to identify TMPRSS2:ERG+ cases with intra-
chromosomal deletion between TMPRSS2 and ERG, which
has also been associated with aggressive disease in some
cohorts [5,8]. In conclusion, the results reported herein
support large-scale studies in prospective cohorts to deter-
mine the specificity and the sensitivity of urine-based assays
for the detection of prostate cancer.
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Figure 2. Confirmation of the presence or the absence of TMPRSS2:ERG
detection in the urine using FISH on matched tissue sections. Matched
prostate cancer tissue samples for five samples were assessed by FISH for
TMPRSS2:ERG fusion using a split-probe assay for ERG rearrangement
(Table 1). Hematoxylin and eosin staining (A and B) and representative FISH
images (C and D) for samples 5778 and 5790 are shown. A negative FISH
assay (C) for sample 5778 is indicated by two pairs of colocalized red and
green signals (yellow arrows) per cell, whereas a positive FISH assay is
indicated by one pair of split red and green signals (not shown) or exclusive
loss of the 5 V ERG probe (red signal) resulting in one pair of colocalized
signals (yellow arrows) and one green signal (green arrows) per cell (D), as
shown for sample 5790.
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